I expect we'll here (and see) more about the Patient Experience Program over this quarter, leading into public sales launch next quarter.
I don't see it as a deliberate omission, but rather a tweak to the plan where they have decided to run with a Patient Experience Program to better promote Sofdra when it is launched to the general public. I see it as a good thing for sales, marketing and publicity which will only help Sofdra snare huge market share. The Patient Experience Program will actually help BOT to market Sofdra even more effectively prior to launch. Personally, I think it's a brilliant plan!
BOT - Anything but charting, page-8987
-
- There are more pages in this discussion • 483 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add BOT (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
37.0¢ |
Change
-0.005(1.33%) |
Mkt cap ! $669.7M | |||
| Open | High | Low | Value | Volume |
| 37.5¢ | 39.0¢ | 37.0¢ | $1.603M | 4.223M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 378157 | 37.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 37.5¢ | 98000 | 5 |
View Market Depth
| Last trade - 16.10pm 26/07/2024 (20 minute delay) ? |
| BOT (ASX) Chart |